ReviewInternational journal of nanomedicine2026
Polymeric Nanomedicines for siRNA Delivery in Hepatocellular Carcinoma: Emerging Therapeutic Strategies, Combination Approaches, and Translational Perspectives.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Hepatocellular carcinoma is the sixth most common cancer worldwide and a leading cause of cancer related mortality. Risk factors include chronic hepatitis B/C, obesity, alcohol abuse, diabetes and metabolic disorders. In advanced stages, normal treatments such as surgery, transplantation and chemotherapy are not as effective as tumors develop resistance and do not target oncogenic pathways well. Small interfering RNA (siRNA) therapeutics have the potential to change treatment paradigms by silencing specific biological pathways, thus suppressing tumor progression. Polymeric nanoparticles (PNPs) such as poly(lactic-co-glycolic acid) (PLGA), polyethyleneimine (PEI) and stimuli-responsive copolymers have attracted attention as effective delivery systems for siRNA. These carriers protect siRNA from enzymatic degradation and facilitate its cellular uptake. Furthermore, the surface of the carriers can be modified with targeting ligands, eg, galactose or ASGPR antibodies, to improve tumor-specific delivery. The PNPs can be tuned to change their physical and chemical properties, are more stable and responsive to signals from the tumor microenvironment for regulated release. This means they perform better than lipophilic or metallic carriers. Hepatocyte specific absorption pathways even enhance the liver tropism. This review focuses on recent advances in siRNA based therapeutic strategies against hepatocellular carcinoma, with a special focus on PNPs mediated drug delivery systems. It describes significant oncogenic pathways like β-catenin and STAT3 and formulation techniques including nanoprecipitation and layer by layer assembly. The review also reports the increasing importance of artificial intelligence in siRNA design, formulation optimization, and personalized therapeutic methods to improve the clinical applicability of HCC treatment.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.